Primer: Sirnaomics (2257 HK) - Oct 2025
Sirnaomics is a clinical-stage biopharmaceutical company specializing in the discovery and development of RNA interference (RNAi) therapeutics,...
561 Views
APAC Healthcare Weekly (March 22) – Hengrui, Microport Neuro, Celltrion, Samsung Bio, Sun Pharma
Celltrion signed KRW375B biologics CMO deal with a global pharma company. Samsung Bioepis expands biosimilar collaboration with Sandoz. 40+ Indian...
318 Views
China Healthcare Weekly (Nov.11)-Largest Spring Coil VBP; Biological Drug VBP; FDA Changes Game Rule
The largest spring coil VBP led by Jilin has certain reference significance. Biological drugs may be included in 8th national VBP.After FDA changes...
456 Views
Ribo Life Science (6938 HK): Madrigal MASH Deal A Positive, But Still a Long Waiting Game
​Suzhou Ribo Life Science partners with Madrigal Pharmaceuticals for siRNA programs targeting MASH. Upfront payments etc are fine, but Ribo Life is...
202 Views
Pre-IPO Sirius Therapeutics - The Pipeline and the Concerns Behind
SRSD107 and SRSD216 have blockbuster potential,but will face R&D failure risk and uncertainties in commercialization.Sirius' lack of commercialized...
238 Views